Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 May;24(5):458-471.
doi: 10.1016/j.molmed.2018.03.005. Epub 2018 Apr 14.

IL-1 Family Cytokine Pathways Underlying NAFLD: Towards New Treatment Strategies

Affiliations
Review

IL-1 Family Cytokine Pathways Underlying NAFLD: Towards New Treatment Strategies

Andreea-Manuela Mirea et al. Trends Mol Med. 2018 May.

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide. Pathways responsible for the activation of IL-1 family cytokines are key in the development of NAFLD but underlying mechanisms are not fully understood. Many studies have focused on the inflammasome-caspase-1 pathway and have shown that this pathway is an important inducer of inflammation in NAFLD. However, this pathway is not solely responsible for the activation of proinflammatory cytokines. Also, neutrophil serine proteases (NSPs) are capable of activating cytokines and recent studies reported that these proteases also contribute to NAFLD. These studies provided, for the first time, evidence that this inflammasome-independent pathway is involved in NAFLD. In our opinion, these new insights open up new approaches for therapeutic intervention.

Keywords: inflammasome; inflammation; interleukin-1; neutrophil serine proteases; nonalcoholic fatty liver disease; obesity.

PubMed Disclaimer

Conflict of interest statement

Competing interests

The authors declare to have no competing interests

Figures

Figure 1
Figure 1. The role of the NLRP3 inflammasome in IL-1 family cytokine activation.
Activation of the NLRP3 inflammasome and IL-1 family cytokines is a two-step process. In the first step (1) a PAMP, such as LPS, binds to its receptor (TLR4 for LPS) and activates via the adaptor protein MyD88 the transcription factor NF-kB. Next, NF-kB will translocate to the nucleus and up regulates the transcription of genes encoding for the NLRP3 protein complex and the pro-inflammatory cytokines IL-1β and IL-18. In the second step (2), a DAMP signal leads to association of the NLRP3 complex and activation of the effector protein caspase-1. In turn, caspase-1 cleaves pro-IL-1β and pro-IL-18 thereby releasing their active forms. These cytokines will be excreted from the cells and promote local (and systemic) inflammation. LPS: lypopolysacharide; TLR4: toll-like receptor; MyD88: myeloid differentiation primary response 88; NF-kB: nuclear factor kB; DAMP: damage associated molecular pattern; ASC: apotosis like associated protein containing a CARD domain (component of the inflammasome); NLRP3: NOD like receptor associated protein 3; (pro)-IL-1β: (pro) interleukin-1β; (pro)- IL-18: (pro)- interleukin 18.
Figure 2
Figure 2. The role of neutrophil serine proteases in IL-1 family cytokine activation
NSPs are stored in the azurophilic granules of neutrophils. Upon neutrophil activation, neutrophil serine proteases will be released into the cytosol (1) where they can activate pro-inflammatory cytokines. They can also be released into the phagolysosome where they have antimicrobial effects (2) or outside the cell where they can bind to the membrane (3) and activate extracellular cytokines, form NETs (4) and migrate into the extracellular space and activate pro-inflammatory cytokines (5). In the extracellular matrix AAT can inhibit NSPs which leads to the inhibition of cytokine activation (5).

Comment in

References

    1. European Association for the Study of the L, European Association for the Study of D, European Association for the Study of O. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Journal of hepatology. 2016;64(6):1388–402. - PubMed
    1. Calzadilla Bertot L, Adams LA. The Natural Course of Non-Alcoholic Fatty Liver Disease. International journal of molecular sciences. 2016;17(5) - PMC - PubMed
    1. Kakino S, Ohki T, Nakayama H, Yuan X, Otabe S, Hashinaga T, et al. Pivotal Role of TNF-alpha in the Development and Progression of Nonalcoholic Fatty Liver Disease in a Murine Model. Horm Metab Res. 2017 - PubMed
    1. Negrin KA, Roth Flach RJ, DiStefano MT, Matevossian A, Friedline RH, Jung D, et al. IL-1 signaling in obesity-induced hepatic lipogenesis and steatosis. PloS one. 2014;9(9):e107265. - PMC - PubMed
    1. Szabo G, Petrasek J. Inflammasome activation and function in liver disease. Nature reviews Gastroenterology & hepatology. 2015;12(7):387–400. - PubMed

Publication types

MeSH terms